[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wugen, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100555646","phase-2-a-phase-2-study-of-wu-cart-007-an-anti-cd7-allogeneic-car-t-cell-therapy-in-t-cell-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-t-rrex-100555646",false,"NCT06514794","A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Cell Acute Lymphoblastic Leukemia\u002FLymphoblastic Lymphoma (T-RRex)","Key Inclusion Criteria:\n\n* Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse\u002Frefractory or MRD positive\n* Age: Lower age limit of ≥ 6 months; adequate organ function\n* Eastern Cooperative Oncology Group (ECOG)\u002FKarnofsky Performance Status 0 or 1\u002F70 and above at Screening.\n\nKey Exclusion Criteria:\n\n* Prior treatment with any anti-CD7 therapy.\n* Patients with decompensated hemolytic anemia.\n* Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.","ALL","1 Year",{"count":19,"type":20},125,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed\u002FRefractory (R\u002FR) T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u002FLymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response",[26,27],"T-cell Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[29],"CAR-T Therapy","RECRUITING","2026-05-09",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":34},"2025-01-31",{"date":38,"type":20},"2028-12-30",{"name":40,"class":41},"Wugen, Inc.","INDUSTRY",15,""]